anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Traditionally, percutaneous nephrolithotomy (PCNL) includes placing a nephrostomy tube and a Double J (DJ) stent to drain the kidney and operative tract following the procedure. However, more recent techniques, such as tubeless or totally tubeless PCNL, eliminate these drainage methods. The objective was to assess the feasibility, safety and effectiveness of performing tubeless or totally tubeless PCNL in comparison to standard PCNL a retrospective analysis was performed on 156 patients who underwent PCNL treatment From September 2022 to September 2023. Of these, 78 patients received traditional nephrostomy PCNL, while 46 patients underwent the tubeless procedure and the remaining 32 received the totally tubeless procedure. The three groups showed no significant differences in preoperative patient characteristics. The operation time, analgesic requirements and hospital stay were lower in the tubeless and totally tubeless PCNL group than in the standard PCNL group (p<0.05). No significant differences were found in the mean stone size, stone-free status or the occurrence of major complications. The overall complications (Grade-1, 2 and 3) rate was 14.2% in the standard PCNL group, 8.7% in the tubeless PCNL and 9.4% in the totally tubeless PCNL group. The tubeless and totally tubeless PCNL techniques have proven to be safe and effective, even for patients with incomplete staghorn stones and a moderate pelvic stone burden. These approaches are associated with reduced pain, lower analgesic needs, shorter operative times, and decreased hospital stays, making them more cost- effective and less likely to result in complications, while also improving patient satisfaction. Further research is essential to validate the safety of these techniques, encouraging urologists to adopt them in clinical practice.
OBJECTIVES: Previous studies have indicated that compared to older adults, younger older adults (e.g., baby boomers) are more susceptible to obesity, but their risk decreases as they age. However, there is a lack of research on how individuals experience sarcopenic obesity, which increases in later life and is a mortality risk factor. This study examined how younger cohorts of older Americans and their demographic traits are related to sarcopenic obesity.
METHODS: Generalized estimating equations were used to analyze participants aged 65 years and older, stratified by sex using data from the 2006-2016 Health and Retirement Study, with survey weights (n = 2,896 men and n = 4,268 women).
RESULTS: The findings indicate that the youngest cohort (born between 1948 and 1953) had greater odds of sarcopenic obesity than older cohorts (born before 1931). However, the youngest cohort did not have significantly different risks from those born between 1931 and 1947. Unexpectedly, the youngest cohort of older women living alone tended not to have sarcopenic obesity compared to the older cohorts living alone. These results remained significant even after adjusting for various covariates, including marital status, race, education level, wealth, and other factors.
DISCUSSION: This paper contributes to the existing literature on population health and demographic change in 2 ways. First, the risk of sarcopenic obesity is higher among younger cohorts of older Americans relative to older cohorts (born before 1931). Second, living alone may not necessarily be considered a worse health condition, particularly for younger female cohorts.
A biosensor system determines analyte concentration from an output signal generated from a light-identifiable species or a redox reaction of the analyte. The biosensor system compensates at least 50% of the total error in the output signal with a primary function and may compensate a portion of the residual error with at least one residual function. An SSP function may serve as the primary function, first residual function, or second residual function. Preferably, when the SSP function serves as the first residual function, the SSP function compensates at least 50% of the residual error remaining after primary compensation. Preferably, when the SSP function serves as the second residual function, the SSP function compensates at least 50% of the residual error remaining after primary and first residual compensation. The error compensation provided by the primary, first residual, and second residual functions may be adjusted with function weighing coefficients.
BACKGROUND: Breast cancer (BC) remains a significant contributor to female mortality globally, with inflammation and the immune system implicated in its pathogenesis. To elucidate potential causal relationships, we evaluated the relationship among 731 immune cell phenotypes and BC be at risk by using Mendelian randomization (MR), while also exploring inflammatory proteins as mediators in this association.
METHODS: We obtained immune cell genome-wide association study (GWAS) summary data and 91 inflammatory factors from the GWAS Catalog. BC GWAS data was obtained from the IEU Open GWAS project (ukb-b-16890 for discovery and GCST004988 for validation). We investigated the causal link between immune cells and BC risk by employing a two-sample MR method. Furthermore, we use a two-step MR to quantify the percentage of mediation of immune cell-BC causal effects mediated by inflammatory proteins. To make sure the causal findings were robust, a sensitivity analysis was done.
RESULTS: In both discovery and validation GWAS, a critical inverse correlation between CD4+ T cells and BC risk was found using MR analysis (Discovery: OR, 0.996; P = 0.030. Validation: OR, 0.843; P = 4.09E-07) with Caspase 8 levels mediating 18.9% of the reduced BC risk associated with immune cells(Mediation proportion=a×b/c, Discovery:0.151×-0.005/-0.004 = 18.9%; Validation:0.151×-0.214/-0.171 = 18.9%).
CONCLUSION: Our study establishes a causal connection linking CD4+ T cells and BC, with Caspase 8 levels partially mediating this relationship. These findings enhance our genetic and molecular comprehension of BC, suggesting potential pathways for future BC immunotherapy drug development.
BACKGROUND: Total elbow arthroplasty (TEA) is an appropriate surgical treatment option for a variety of conditions ranging from inflammatory arthritis to trauma. Because of a high complication profile, implant companies have attempted to improve patient outcomes with evolving design mechanics and philosophy. However, the Nexel TEA prosthesis has been criticized for its unacceptably high revision rate by other research groups in the literature. The purpose of this study was to evaluate the survivorship and revision rates of the Nexel and Coonrad-Morrey TEA implant systems in New Zealand.
METHODS: Prospectively collected National Joint Registry data were used to compare the survival rates of these prostheses. Underlying diagnoses, reasons for revision, and patient demographics were all recorded. Statistical analysis included survival analysis using Kaplan-Meier curves and comparison between groups using independent t tests.
RESULTS: Over the 23-year study interval, the Nexel and Coonrad-Morrey prostheses showed similar survivorship and revision rates. The revision rates at 5 years were 7.3% for Nexel and 4.5% for the Coonrad-Morrey cohorts. The average time to revision for those who are revised was 3.13 ± 1.74 years in the Nexel group and 4.93 ± 4.13 years in the Coonrad-Morrey population.
CONCLUSION: Our study confirms a lower revision rate of the Nexel TEA compared to other studies in the literature. Additionally, the Nexel TEA implant performs comparably to its predecessor, the Coonrad-Morrey prosthesis in New Zealand. Although it is difficult to explain the discrepancy in results with the study by Morrey et al, future studies should focus on investigating postoperative radiographs and a deep analysis of the specific surgical technique used for this implant.
PROBLEM TO BE SOLVED: To provide a therapy for treating cancer cells and for preventing intercellular gap formation, which is said to be a cause of cancer, in the peripheral cells. SOLUTION: In the therapy for viral, mycotic and other microbial diseases, an antibacterial galenical and a health-improving food are used. The antibacterial galenical comprises powder of leaves and stems of Chinese herbal medicine Agrimonia pilosa Ledeb., powder of leaves and stems of Chinese herbal medicine Scutellaria barbata, powder of leaves and stems of Chinese herbal medicine Houttuynia cordata, powder of stems of Chinese herbal medicine Oldenlandia diffusa (Wild.) Roxb., and powder of stems of Chinese herbal medicine Gynostemma pentyphyllum. The health-improving food comprises powder of Phaseolus radiatus, powder of Coix lachryna-obi L. Var. mayuen Stapf, powders of glutinous kaoliang, oat germ and wheat germ.
After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: Doravirine Type 1 dose (150 mg tablet \[40% drug loaded granule\]). During Period 2, participants received Treatment A: Doravirine 100 mg film coated tablet. During Period 3, participants received Treatment C: Doravirine Type 2 dose (150 mg tablet \[30% drug loaded granule\]). During Period 4, participants received Treatment D: Doravirine Type 3 dose (150 mg tablet \[50% drug loaded granule\]. During Period 5, participants received Treatment E: Doravirine Type 4 dose (100 mg tablet \[30% drug loaded granule\]). Each period was separated by a 14 day washout.
PURPOSE: A cell-permeable peptide or mutant thereof is provided to a large molecular substance into cytoplasm or nucleus and each organ. CONSTITUTION: A cell-permeable peptide is denoted by amino acid of sequence number 1. A fused body contains the cell-permeable peptide and biologically active substance. The biologically active substance is DNA, RNA, protein, lipid, carbohydrate, or chemical compounds. The chemical compounds are an anticancer drug, therapeutic agent for immune disease, antibiotics, or factor for growth, development, or differentiation. A composition for intracellular delivery of biologically active substance contains the fused body as an active ingredient. A composition for gene therapy contains the fused body as an active ingredient.
Exosomes have garnered attention as a potential cell-free therapy for inflammatory diseases due to their immunomodulatory and anti-inflammatory properties. Exosome-like nanoparticles isolated from Arbutus unedo were characterized and analyzed for their anti-inflammatory potential. The results revealed that the isolated exosomes exhibited a spheroid morphology, with an approximate modal size of 190 nm. Exposure to these exosomes significantly reduced the mRNA expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), the glycoprotein CD80, the transcription factor STAT1, and pro-inflammatory cytokine genes like IL-1b and IL-6, in lipopolysaccharide (LPS)-induced protein RAW264.7 cells. In addition, exosomes reduced the LPS-induced protein levels of PSTAT1 and STAT1, IRF1 and RelB, which are key transcription factors in the control of proinflammatory gene expression. LC-MS analysis identified the presence of carotenoids, mainly β-carotene, with known anti-inflammatory activity, related to its ROS-scavenging activity, suggesting its potential contribution to the anti-inflammatory activity of the exosomes isolated from A. unedo fruits.
We consider a heterogeneous, globally coupled population of excitatory quadratic integrate-and-fire neurons with excitability adaptation due to a metabolic feedback associated with ketogenic diet, a form of therapy for epilepsy. Bifurcation analysis of a three-dimensional mean-field system derived in the framework of next-generation neural mass models allows us to explain the scenarios and suggest control strategies for the transitions between the neurophysiologically desired asynchronous states and the synchronous, seizure-like states featuring collective oscillations. We reveal two qualitatively different scenarios for the onset of synchrony. For weaker couplings, a bistability region between the lower- and the higher-activity asynchronous states unfolds from the cusp point, and the collective oscillations emerge via a supercritical Hopf bifurcation. For stronger couplings, one finds seven co-dimension two bifurcation points, including pairs of Bogdanov-Takens and generalized Hopf points, such that both lower- and higher-activity asynchronous states undergo transitions to collective oscillations, with hysteresis and jump-like behavior observed in vicinity of subcritical Hopf bifurcations. We demonstrate three control mechanisms for switching between asynchronous and synchronous states, involving parametric perturbation of the adenosine triphosphate (ATP) production rate, external stimulation currents, or pulse-like ATP shocks, and indicate a potential therapeutic advantage of hysteretic scenarios.
Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions:

Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci.

Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria.

Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis.

Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis.

Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy.

Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing.

It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Indicated surgical procedures should be performed.
Cetuximab \[250mg/m2 (day 1, weekly x10)\] + FHX (5-FU \[CI: 600mg/m2/day; days 0-5 (120h total) every other week x5\], Hydroxyurea \[500 mg PO BID, days 0-5 (=11 doses), every other week x5\] and twice-daily radiation \[150 cGy per fraction - days 1-5, every other week x5 (70-72 Gy total dose)\]). Total duration is 10 weeks.
INTRODUCTION: A change from the supine to prone position causes hemodynamic alterations. We aimed to evaluate the effect of fluid preloading in the supine position, the subsequent hemodynamic changes in the prone position and postoperative outcomes.
PATIENTS AND METHODS: This prospective, assessor-blind, randomized controlled trial was conducted between March and June 2023. Adults scheduled for elective orthopaedic lumbar surgery under general anaesthesia were enrolled. In total, 80 participants were randomly assigned to fluid maintenance (M) or loading (L) groups. Both groups were administered intravenous fluid at a rate of 2 ml/kg/h until surgical incision; Group L was loaded with an additional 5 ml/kg intravenous fluid for 10 min after anaesthesia induction. The primary outcome was incidence of hypotension before surgical incision. Secondary outcomes included differences in the mean blood pressure (mBP), heart rate, pleth variability index (PVi), stroke volume variation (SVV), pulse pressure variation (PPV), stroke volume index and cardiac index before surgical incision between the two groups. Additionally, postoperative complications until postoperative day 2 and postoperative hospital length of stay were investigated.
RESULTS: Hypotension was prevalent in Group M before surgical incision and could be predicted by a baseline PVi >16. The mBP was significantly higher in Group L immediately after fluid loading. The PVi, SVV and PPV were lower in Group L after fluid loading, with continued differences at 2-3 time points for SVV and PPV. Other outcomes did not differ between the two groups.
CONCLUSION: Fluid loading after inducing general anaesthesia could reduce the occurrence of hypotension until surgical incision in patients scheduled for surgery in the prone position. Additionally, hypotension could be predicted in patients with a baseline PVi >16. Therefore, intravenous fluid loading is strongly recommended in patients with high baseline PVi to prevent hypotension after anaesthesia induction and in the prone position.
TRIAL NUMBER: KCT0008294 (date of registration: 16 March 2023).
PURPOSE:To provide the subject compound having remarkably increased antibacterial activity especially against clinical isolate, free from convulsion-inducing action caused by the combined use with anti-inflammatory agent and useful as an antibacterial agent, anti-tumor agent and therapeutic agent for AIDS. CONSTITUTION:The compound of formula I (R<1> is H or lower alkyl; R<2> is H, carboxylic acid ester residue, etc.; C atom labeled with * is asymmetric C atom having absolute configuration of R or S) and its salt, e.g. (1S,3'S)-7-(3- amino-1-pyrrolidinyl)-6-fluoro-1-methyl-4-oxo-1H,4H-[1,3]thiazeto[3,2- a]quinoline-3- carboxylic acid. The compound can be produced by reducing and dehalogenating an optically active 8-halogenothiazetoquinoline-3-carboxylic acid derivative of formula II (X is halogen) and, as necessary, hydrolyzing the product. The compound of formula II is also a new compound, which can be produced e.g. by reacting a compound of formula III (Y is X) with a compound of formula IV and halogenating the reaction product.
An improved porous ceramic body to be embedded in a patient for sustained release of a medicament, and a method of making the ceramic body is provided. To control the release of the medicament, the pores of the ceramic body decrease in diameter from the inner surface to the outer surface of the body whereby the pore diameter is substantially proportional to the distance from the outer surface of the carrier.First, raw ceramic slurry is made from the blend of beta-TCP, deflocculating agent, and water. Next, using a syringe the ceramic slurry is supplied to the internal region of a solvent-absorbable mold from an aperture along the inner wall surface. Then, the ceramic slurry is quickly dehydrated before thinly adhering itself onto the inner wall surface of the mold. Therefore, a preformed body having a hollow is obtained. Next, after fully being dried, the dried preformed body is fired at 1,050° C. for an hour before eventually yielding a spherical carrier for use in sustained release preparation. Substantially, the carrier is composed of a porous ceramic body which having the hollow for retaining the medicament and permits permeation of the medicament. The pore diameter corresponding to the peak value of the distribution thereof decreases toward to the outer periphery of the preformed body and yet, width of the distribution of the pore diameter becomes narrower.
PURPOSE: A pharmaceutical composition containing Bambusae Caulis in Liquamen is provided to suppress NO generation and remove free radical. CONSTITUTION: A pharmaceutical composition for treating or preventing oxidative injury caused by inflammatory disease or free radical contains pharmaceutically effective amount of Bambusae Caulis in Liquamen extract and pharmaceutically acceptable carrier. The pharmaceutical compositioin also contains pharmaceutically effective amount of 1,2-dihydroxybenzene or 1,4-dihydroxybenzene and pharmaceutically acceptable carrier. The 1,2-dihydroxybenzene or 1,4-dihydroxybenzene is isolated from Bambusae Caulis in Liquamen extract. The inflammatory disease is sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, atopic dermatitis, inflammatory bowel disease, inflammatory collagen vascular diseases, glomerulonephritis, inflammatory skin diseases or sarcoidosis. The oxidative injury is atherosclerosis, cancer, emphysema, cirrhosis, or arthritis.
The invention relates to the technical field of biology, in particular to a nano antibody GN1 specifically combined with GPC3 protein; the nanobody GN1 consists of the variable region of a heavy chain antibody; the variable region of the heavy chain antibody comprises an epitope-complementing region and a framework region; said framework regions are selected from the group consisting of FR1, FR2, FR3 and FR4 and their homologous sequences, and said epitope-complementing regions are selected from the group consisting of CDR1, CDR2 and CDR3 and their homologous sequences; the amino acid sequences of the CDRs 1-3 have the sequences shown as SEQ ID NO. 1-3; the amino acid sequence of FR1-4 has a sequence as shown in SEQ ID NO. 4-7. The amino acid sequence of the antibody is SEQ ID NO.8, and the nucleotide sequence for coding the amino acid is SEQ ID NO. 9. The nano antibody GN1 can be specifically bound with liver cancer cells with high expression of GPC3 protein, and can inhibit the proliferation of the liver cancer cells. The amino acid sequence of the nano antibody GN1 or the nucleotide sequence of the nano antibody GN1 or the recombinant plasmid containing the nucleotide sequence or the recombinant cell containing the nucleotide sequence recombinant plasmid can be applied to the research and development of diagnostic reagents and the medicine for treating liver cancer.
Furosemide is a diuretic which is an anthranilic acid derivative. Furosemide tablets, USP for oral administration contain furosemide, USP as the active ingredient and the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, pregelatinized starch, and sodium starch glycolate. Chemically, it is 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid. Furosemide , USP is available as white to off white round tablets for oral administration in dosage strengths of 20, 40 and 80 mg. Furosemide, USP is a white to slightly yellow odorless crystalline powder. It is practically insoluble in water, soluble in 15 parts of acetone, freely soluble in dimethylformamide and in solution of alkali hydroxides; soluble in methanol; sparingly soluble in alcohol; very slightly soluble in chloroform.

The CAS Registry Number is 54-31-9.

It has a molecular formula of C12H11ClN2O5S and a molecular weight of 330.75.

The molecular structure is as follows:

Tested by USP Dissolution Test 1